Overuse of antibiotics in medicine and farming has led to the rise of antibiotic resistant bacteria worldwide.
The rise of superbugs is a global health issue and one of the leading threats to human health according to the World Health Organisation.
Recce Pharmaceuticals has developed a new generation of antibiotic therapies to address the rise of antibiotic resistant superbugs.
Our portfolio of new antibiotic therapies holds the potential to help address the threat to human health posed by drug resistant bacteria.
Our lead candidate RECCE®327 is designed to be a broad spectrum antibiotic, formulated using synthetic polymer technology to treat bacterial sepsis (blood poisoning).
RECCE®327 was recently recognised by the US Food and Drug Authority (FDA) through the award of Qualified Infectious Disease Product (QIDP) status - a legal status awarding expedited review and 10 year market extensions.
Recce Pharmaceuticals is currently in discussions with the US Food & Drug Administration (FDA) to gain approval to test its therapy in humans.
With a low cost, out-sourced business model and a strong patent portfolio, the business is well positioned, with management committed to delivering long-term value to shareholders.
The social and economic cost of antibiotic resistance
Antibiotic resistance currently accounts for an estimated 50,000 deaths in the US and Europe. The estimated current death toll worldwide is 700,000.
If antibiotic resistance were allowed to grow unchecked, the number of deaths per year would grow to 10 million by 2050. That is more than the 8.2 million per year who currently die of cancer and 1.5 million who die of diabetes, combined.
Those deaths would cost the world up to 3.5 percent of its total gross domestic product, or up to US$100 trillion by 2050.